Syndecan 4 is involved in mediating HCV entry through interaction with lipoviral particle-associated apolipoprotein E

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Lefèvre, Mathieu ^a,b   Felmlee, Daniel J ^a,b   Parnot, Marie ^a,b   Baumert, Thomas F ^a,b,c   Schuster, Catherine ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; APOLIPOPROTEIN E; PROTEOHEPARAN SULFATE; SMALL INTERFERING RNA; SYNDECAN 1; SYNDECAN 4; LIPID; PROTEIN BINDING;

ARTICLE; CONTROLLED STUDY; HEPATITIS C VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; NONHUMAN; PROTEIN PROTEIN INTERACTION; VIRUS ENTRY; VIRUS INFECTIVITY; AMINO ACID SEQUENCE; CELL LINE; CHEMISTRY; HEPACIVIRUS; HEPATITIS C; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; VIROLOGY;

AMINO ACID SEQUENCE; APOLIPOPROTEINS E; CELL LINE; HEPACIVIRUS; HEPARAN SULFATE PROTEOGLYCANS; HEPATITIS C; HUMANS; LIPIDS; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SYNDECAN-4; VIRUS INTERNALIZATION;

EID: 84899698156     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095550     Document Type: Article

References (43)

1. Chung RT, Stravitz RT, Fontana RJ, Schiodt FV, Mehal WZ, et al. (2012) Pathogenesis of liver injury in acute liver failure. Gastroenterology 143: e1-7.
2. Schaefer EA, Chung RT (2012) Anti-hepatitis C virus drugs in development. Gastroenterology 142: 1340-1350 e1341.
3. Zeisel MB, Barth H, Schuster C, Baumert TF (2009) Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy. Front Biosci 14: 3274-3285.
4. Merz A, Long G, Hiet MS, Brugger B, Chlanda P, et al. (2011) Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J Biol Chem 286: 3018-3032.
5. Catanese MT, Uryu K, Kopp M, Edwards TJ, Andrus L, et al. (2013) Ultrastructural analysis of hepatitis C virus particles. Proc Natl Acad Sci U S A 110: 9505-9510.
6. Meunier JC, Russell RS, Engle RE, Faulk KN, Purcell RH, et al. (2008) Apolipoprotein c1 association with hepatitis C virus. J Virol 82: 9647-9656.
7. Felmlee DJ, Hafirassou ML, Lefevre M, Baumert TF, Schuster C (2013) Hepatitis C virus, cholesterol and lipoproteins-impact for the viral life cycle and pathogenesis of liver disease. Viruses 5: 1292-1324.
8. Benga WJ, Krieger SE, Dimitrova M, Zeisel MB, Parnot M, et al. (2010) Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles. Hepatology 51: 43-53.
9. Chang KS, Jiang J, Cai Z, Luo G (2007) Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J Virol 81: 13783-13793. (Pubitemid 350247871)
10. Jiang J, Cun W, Wu X, Shi Q, Tang H, et al. (2012) Hepatitis C virus attachment mediated by apolipoprotein e binding to cell surface heparan sulfate. J Virol 86: 7256-7267.
11. Owen DM, Huang H, Ye J, Gale M, Jr. (2009) Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology 394: 99-108.
12. Albecka A, Belouzard S, Op de Beeck A, Descamps V, Goueslain L, et al. (2012) Role of low-density lipoprotein receptor in the hepatitis C virus life cycle. Hepatology 55: 998-1007.
13. Manon-Jensen T, Itoh Y, Couchman JR (2010) Proteoglycans in health and disease: the multiple roles of syndecan shedding. FEBS J 277: 3876-3889.
14. Deng Y, Foley EM, Gonzales JC, Gordts PL, Li Y, et al. (2012) Shedding of syndecan-1 from human hepatocytes alters very low density lipoprotein clearance. Hepatology 55: 277-286.
15. Stanford KI, Bishop JR, Foley EM, Gonzales JC, Niesman IR, et al. (2009) Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J Clin Invest 119: 3236-3245.
16. MacArthur JM, Bishop JR, Stanford KI, Wang L, Bensadoun A, et al. (2007) Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. J Clin Invest 117: 153-164. (Pubitemid 46048462)
17. Krieger SE, Zeisel MB, Davis C, Thumann C, Harris HJ, et al. (2010) Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology 51: 1144-1157.
18. Koutsoudakis G, Kaul A, Steinmann E, Kallis S, Lohmann V, et al. (2006) Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol 80: 5308-5320.
19. Zeisel MB, Koutsoudakis G, Schnober EK, Haberstroh A, Blum HE, et al. (2007) Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology 46: 1722-1731.
20. Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, et al. (2006) Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A 103: 7408-7413. (Pubitemid 43727846)
21. Morgan M R, Hamidi H, Bass M D, Warwood S, Ballestrem C, et al. (2013) Syndecan-4 Phosphorylation Is a Control Point for Integrin Recycling. Developmental cell 24: 472-485.
22. Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A, et al. (1996) Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 70: 4805-4810. (Pubitemid 26187479)
23. Wolf M, Dimitrova M, Baumert TF, Schuster C (2008) The major form of hepatitis C virus alternate reading frame protein is suppressed by core protein expression. Nucleic Acids Res 36: 3054-3064. (Pubitemid 351737197)
24. Dimitrova M, Imbert I, Kieny MP, Schuster C (2003) Protein-protein interactions between hepatitis C virus nonstructural proteins. J Virol 77: 5401-5414. (Pubitemid 36460954)
25. Morikawa K, Zhao Z, Date T, Miyamoto M, Murayama A, et al. (2007) The roles of CD81 and glycosaminoglycans in the adsorption and uptake of infectious HCV particles. J Med Virol 79: 714-723. (Pubitemid 46709365)
26. Zona L, Lupberger J, Sidahmed-Adrar N, Thumann C, Harris HJ, et al. (2013) HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe 13: 302-313.
27. Sandrin V, Boulanger P, Penin F, Granier C, Cosset FL, et al. (2005) Assembly of functional hepatitis C virus glycoproteins on infectious pseudoparticles occurs intracellularly and requires concomitant incorporation of E1 and E2 glycoproteins. J Gen Virol 86: 3189-3199. (Pubitemid 41685150)
28. Barth H, Schafer C, Adah MI, Zhang F, Linhardt RJ, et al. (2003) Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 278: 41003-41012. (Pubitemid 37280923)
29. Masciopinto F, Giovani C, Campagnoli S, Galli-Stampino L, Colombatto P, et al. (2004) Association of hepatitis C virus envelope proteins with exosomes. Eur J Immunol 34: 2834-2842. (Pubitemid 39430159)
30. Pietschmann T, Lohmann V, Kaul A, Krieger N, Rinck G, et al. (2002) Persistent and transient replication of full-length hepatitis C virus genomes in cell culture. J Virol 76: 4008-4021. (Pubitemid 34250565)
31. Long G, Hiet MS, Windisch MP, Lee JY, Lohmann V, et al. (2011) Mouse hepatic cells support assembly of infectious hepatitis C virus particles. Gastroenterology 141: 1057-1066.
32. Linton MF, Gish R, Hubl ST, Butler E, Esquivel C, et al. (1991) Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J Clin Invest 88: 270-281.
33. Libeu CP, Lund-Katz S, Phillips MC, Wehrli S, Hernaiz MJ, et al. (2001) New insights into the heparan sulfate proteoglycan-binding activity of apolipoprotein E. J Biol Chem 276: 39138-39144.
34. Gonzales JC, Gordts PL, Foley EM, Esko JD (2013) Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans. J Clin Invest 123: 2742-2751.
35. Barth H, Schnober EK, Zhang F, Linhardt RJ, Depla E, et al. (2006) Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol 80: 10579-10590. (Pubitemid 44628904)
36. Huang H, Sun F, Owen DM, Li W, Chen Y, et al. (2007) Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci U S A 104: 5848-5853. (Pubitemid 47175622)
37. Shi Q, Jiang J, Luo G (2013) Syndecan-1 serves as the major receptor for attachment of hepatitis C virus to the surfaces of hepatocytes. J Virol 87: 6866-6875.
38. Liu S, McCormick KD, Zhao W, Zhao T, Fan D, et al. (2012) Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding. Hepatology 56: 484-491.
39. Krepstakies M, Lucifora J, Nagel C-H, Zeisel MB, Holstermann B, et al. (2012) A New Class of Synthetic Peptide Inhibitors Blocks Attachment and Entry of Human Pathogenic Viruses. Journal of Infectious Diseases 205: 1654-1664.
40. Dobson CB, Sales SD, Hoggard P, Wozniak MA, Crutcher KA (2006) The Receptor-Binding Region of Human Apolipoprotein E Has Direct Anti-Infective Activity. Journal of Infectious Diseases 193: 442-450. (Pubitemid 43122345)
41. Bhattacharjee PS, Neumann DM, Hill JM (2009) A human apolipoprotein E mimetic peptide effectively inhibits HSV-1 TK-positive and TK-negative acute epithelial keratitis in rabbits. Curr Eye Res 34: 99-102.
42. Fafi-Kremer S, Fofana I, Soulier E, Carolla P, Meuleman P, et al. (2010) Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J Exp Med 207: 2019-2031.
43. Fofana I, Fafi-Kremer S, Carolla P, Fauvelle C, Zahid MN, et al. (2012) Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. Gastroenterology 143: 223-233 e229.